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Introduction:  Live-attenuated  inﬂuenza  vaccines  (LAIVs)  have  the  potential  to  be affordable,  effective,  and
logistically  feasible  for immunization  of  children  in  low-resource  settings.
Material and  methods:  We  conducted  a  phase  II, randomized,  double-blind,  parallel  group,  placebo-
controlled  trial  on  the safety  of  the  Russian-backbone,  seasonal  trivalent  LAIV  among  children  aged
24  through  59 months  in  Dhaka,  Bangladesh  in  2012.  After  vaccination,  we  monitored  participants  for
six  months  with  weekly  home  visits  and study  clinic  surveillance  for  solicited  and  unsolicited  adverse
events,  protocol-deﬁned  wheezing  illness  (PDWI),  and  serious  adverse  events  (SAEs),  including  all  cause
hospitalizations.
Results:  Three  hundred  children  were  randomized  and  administered  LAIV  (n  = 150)  or  placebo  (n = 150).  No
immediate  post-vaccination  reactions  occurred  in  either  group.  Solicited  reactions  were  similar  between
vaccine  and  placebo  groups  during  the  ﬁrst  7 days  post-vaccination  and  throughout  the  entire  trial.
There  were  no  statistically  signiﬁcant  differences  in participants  experiencing  PDWI  between  LAIV  and
placebo  groups  throughout  the  trial (n = 13  vs. n  = 16, p = 0.697).  Of  131 children  with  a history  of  medical
treatment  or  hospitalization  for asthma  or wheezing  at study  entry,  65 received  LAIV  and  66  received
placebo.  Among  this  subset,  there  was  no  statistical  difference  in PDWI  occurring  throughout  the  trial
between  the  LAIV  or placebo  groups  (7.7%  vs.  19.7%,  p  = 0.074).  While  there  were  no related  SAEs, LAIV
recipients  had  six  unrelated  SAEs  and  placebo  recipients  had  none.  These  SAEs  included  three  due to
traumatic  injury  and  bone  fracture,  and  one  each  due  to  accidental  overdose  of  paracetamol,  abdominal
pain,  and  acute  gastroenteritis.  None  of the  participants  with  SAEs  had  laboratory-conﬁrmed  inﬂuenza,
wheezing  illness,  or  other  signs  of acute  respiratory  illness  at the  time  of  their  events.
Conclusions:  In this  randomized,  controlled  trial  among  300  children  aged  24 through  59 months  in urban
Bangladesh,  Russian-backbone  LAIV  was  safe  and  well  tolerated.  Further  evaluation  of  LAIV  safety  and
efﬁcacy  in a larger  cohort  is  warranted.
ublis© 2015  The  Authors.  P
. IntroductionAbout 1.8% of infant deaths globally are attributed to inﬂuenza
irus infection [1], and 99% of early childhood deaths due to severe
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
inﬂuenza virus infection occur in developing countries [2]. Never-
theless, most low- and middle-income countries have no policies
regarding prevention of seasonal inﬂuenza virus infection [3].
Inﬂuenza vaccines are effective at preventing inﬂuenza disease,
particularly in young children [4]. Superior efﬁcacy of FluMist®,
a live-attenuated inﬂuenza vaccine (LAIV) based on the inﬂuenza
A/Ann Arbor/6/60 H2N2 and inﬂuenza B/Ann Arbor/1/66 back-
bones (Ann Arbor-backbone LAIV), as compared to inactivated
inﬂuenza vaccine has been demonstrated in children in three
randomized controlled efﬁcacy trials [5–7]. However, because
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
3 ine 33
o
v
l
A
f
B
b
b
c
t
I
w
[
t
t
B
s
i
e
[
d
c
2
2
t
R
t
G
e
o
o
e
g
(
2
p
L
t
u
w
t
(
d
v
2
r
h
o
r
p
v
d
P416 J.R. Ortiz et al. / Vacc
f excess wheezing and hospitalization events occurring in
accinated children younger than two years of age, FluMist® is
icensed for persons two years of age and older [8]. The same Ann
rbor-backbone LAIV is also sold as Fluenz in some countries
A second LAIV was developed in the former Soviet Union
rom attenuated inﬂuenza A/Russian/134/57 (H2N2) and inﬂuenza
/USSR/60/69 master donor viruses (Russian-backbone LAIV), has
een approved for use in children since the 1980s [9]. Russian-
ackbone LAIV seed strains have been provided to developing
ountry vaccine manufacturers through an intellectual property
ransfer program initiated by WHO  [10]. The Serum Institute of
ndia, Ltd. (SIIL1) has recently developed a seasonal trivalent LAIV,
hich is approved for use in India for persons 2 years of age and over
11]. The potential for excess wheezing illness following receipt of
he Russia-backbone LAIV is not known. We  conducted a clinical
rial of the SIIL trivalent, seasonal, LAIV among children in Dhaka,
angladesh to evaluate vaccine safety, with a particular empha-
is on wheezing adverse events. Additional virus shedding and
mmunogenicity studies were performed which provided strong
vidence of a relatively high take rate for all three vaccine strains
12]. They will be described in a separate publication. The trial was
esigned to inform a clinical efﬁcacy trial planned for the same
ommunity if LAIV were demonstrated to be safe and well tolerated.
. Materials and methods
.1. Ethics
This study was reviewed and approved by the International Cen-
re for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) Research
eview and Ethics Review Committees (Dhaka, Bangladesh) and
he Western Institutional Review Board (Olympia, WA,  USA). The
ood Clinical Practice guidelines of the ICH (International Confer-
nce on Harmonisation of Technical Requirements for Registration
f Pharmaceuticals for Human Use) were followed. The study
bjectives, methodology, possible inconveniences, and risks were
xplained to participant parents or guardians in the local lan-
uage (Bangla). The study was registered with ClinicalTrials.gov
NCT01625689).
.2. Study design
This was a phase II, randomized, double-blind, parallel group,
lacebo-controlled trial on the safety of the SIIL Russian-backbone
AIV among children in Dhaka, Bangladesh. The co-primary objec-
ives were: (1) to compare the proportion of solicited and
nsolicited reactions among children receiving LAIV and placebo
ithin the ﬁrst 7 days and 6 months of -vaccination, respec-
ively; and (2) to compare the proportion of serious adverse events
SAEs) and protocol-deﬁned wheezing illness (PDWI) among chil-
ren receiving LAIV and placebo through 42 days and 6 months of
accine administration.
.3. Participants
Children living in Kamalapur Field Site in urban Dhaka were
ecruited for this study [13,14]. Inclusion criteria included: (1)
ealthy male or female child at least 24 months of age and no
lder than 59 months of age at the time of study vaccination; (2)
esidence in the study area; and (3) parent or guardian willing to
rovide written informed consent prior to the participant’s study
accination. Exclusion criteria included: (1) any serious chronic
isease; (2) receiving immunosuppressive agents during the two
1 Nonstandard abbreviations used in text: FRA: Field Research Assistants PDWI:
rotocol-Deﬁned Wheezing Illness SIIL: Serum Institute of India, Ltd. (2015) 3415–3421
weeks prior to study vaccination; (3) documented hypersensitiv-
ity to eggs or other components of the vaccine or life-threatening
reactions to previous inﬂuenza vaccinations; (4) receiving aspirin
therapy currently or two  weeks before; (5) living in a household
with somebody currently participating in a respiratory pathogen
vaccination or antiviral study; (6) current or past participation
(within 2 months of trial enrollment visit) in any clinical trial
involving a drug or biologic with activity against respiratory dis-
ease; or (7) any condition determined by the investigator as likely
to interfere with evaluation of the vaccine or to be a signiﬁcant
potential health risk to the child.
2.4. Randomization and blinding
This trial was randomized in a 1:1 ratio of LAIV to placebo. Both
vaccines were identical in presentation and masked to conceal LAIV
and placebo identiﬁcation. Neither the study physician administer-
ing the vaccine, the participant and family, staff evaluating clinical
illness, nor staff conducting medical monitoring had access to the
vaccine allocation. The vaccinating physician had no involvement
in subsequent vaccine safety or clinical evaluations.
2.5. Vaccine
SIIL donated the LAIV and placebo (lot numbers 166E2001 and
E9001PCB). The active vaccine used the Russian master donor virus
backbone and the placebo contained all components of the vaccine
without the inﬂuenza viruses included. LAIV strains were cold-
adapted to replicate at 25–33 ◦C, temperature sensitive to restrict
replication ≥40 ◦C, and attenuated [15]. LAIV contained the hemag-
glutinin and neuraminidase of the WHO  recommended vaccine
strains for the 2011–2012 Northern Hemisphere inﬂuenza season
[16]. Concentrations of vaccine components were not less than
107 EID50/dose for inﬂuenza A components and not less than 106.5
EID50/dose for the inﬂuenza B component. At the time of vaccina-
tion, a study physician reconstituted the vaccine with sterile water
diluent and administered in a 0.5 ml  intranasal dose (one spray of
0.25 ml  per nostril) via a single-use sprayer device. A single dose of
vaccine was  administered per manufacturer recommendations.
2.6. Safety evaluation and deﬁnitions
Participants were enrolled from June 21, 2012 through July 15,
2012. Those who  consented and met  eligibility criteria received a
single dose of study vaccine and were then observed for 30 min  for
immediate adverse events. Field Research Assistants (FRAs) moni-
tored solicited (nasal congestion/runny nose, stuffy nose, ear pain,
cough, headache, fever, irritability, nausea, sore throat, lethargy)
and unsolicited adverse events during daily home visits for the
ﬁrst 7 days post-vaccination. This duration of daily monitoring was
chosen because in preceding phase II/III SIIL LAIV clinical trials,
imbalances in the solicited adverse events had resolved by 7 days.
FRAs subsequently assessed for solicited adverse events through
weekly home visits through the remainder of the trial. Through
December 2012, FRAs assessed unsolicited adverse events during
weekly home visits, and study physicians did the same during clin-
ical evaluations of children receiving care at the study health clinic.
SAEs were monitored throughout the trial. Adverse events were
graded for severity by FRAs with the exception of SAEs and PDWIs,
which were graded by study physicians. Adverse events were
graded as mild, moderate, severe, or life-threatening, using stan-
dardized grading scales, except for subjective fever, lethargy, and
tachypnea occurring after the ﬁrst week post-vaccination which
were graded as present/absent only. During home visits, partic-
ipants were recommended to seek further evaluation by study
physicians when FRAs determined that participants met referral
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riteria which were deﬁned as either of the following: (1) any
f fever (≥38 ◦C axillary), tachypnea (≥40 breaths/min), chest in-
rawing, lethargy, cyanosis, inability to drink, convulsions, difﬁcult
reathing, noisy breathing, ear pain or discharge; or (2) presence
f both cough and runny nose.
Study physicians examined all participants meeting referral
riteria and presenting to the study clinic (whether referred by FRAs
r self-referred) and used a standardized, data collection instru-
ent to document history of present illness and clinical ﬁndings.
DWI was deﬁned as illness among participants meeting refer-
al criteria, evaluated by study physicians in the study clinic or
articipating hospital, and characterized by a long, high-pitched
histling or musical sound on expiration heard by auscultation
ver the lung ﬁelds. PDWI severity was determined by study physi-
ians and deﬁned as mild (wheezing illness without other ﬁndings
ssociated with moderate or greater severity disease), moderate
nasal ﬂaring, chest in-drawing, or pulse oximetry 90–95%), severe
dyspnea at rest causing inability to perform usual social and func-
ional activities or pulse oximetry <90%), or life threatening. The
DWI deﬁnition was designed to be similar to deﬁnitions of medi-
ally signiﬁcant wheezing used previously [6], and to include illness
urpassing a severity threshold such that incidental wheezing ill-
ess without other signiﬁcant signs or symptoms, such as dyspnea
r tachypnea, was unlikely to be included.
The investigator determined the relationship between the study
accine and adverse events as “related” or “not related”. Events
elated to study vaccine were deﬁned as temporally related to the
dministration of the study vaccine and no other etiology explained
he event. For the purpose of this trial, temporally related was
eﬁned as being within one month of vaccination for PDWI and as
eing within one week of vaccination for all other adverse events.
.7. Sample size determination
Two major considerations informed the sample size choice of
00 participants. First, this sample size was judged by the investiga-
ors to maximize close safety monitoring of the entire cohort while
alancing logistical and feasibility concerns. Second, the sample
ize would allow suitable power to demonstrate signiﬁcant dif-
erences in post-vaccination reactions which have been shown to
e increased with FluMist® in the published literature (including
ever and rhinorrhea), if they were to occur at rates similar to prior
eports [6]. The trial was not designed to have statistical power
o demonstrate signiﬁcant differences in less common outcomes
uch as SAEs or medically signiﬁcant wheeze, if they were to occur
t rates similar to prior reports from larger trials [6].
.8. Data analysis
All analyses and summaries were performed on a modiﬁed
ntention-to-treat basis: only data from those participants who
eceived study vaccine/placebo were analyzed. Primary safety
esults were based on frequencies of participants who had or
cquired the characteristics of interest, regardless of duration of
ollow up. Age categories were 24 through 35 months, 36 through
7 months, and 48 through 59 months. Categorical data were sum-
arized by the number and percentage of participants within each
ategory. Continuous variables, such as measured temperature and
espiratory rate, were summarized according to threshold values
nd summarized as categorical data. Two-sided p values ≤0.05
ere considered statistically signiﬁcant. We  made no multiplicity
djustment for safety endpoints. This was a conservative approach
ince not performing such an adjustment makes it less likely that a
afety signal would be missed. For safety outcomes that may  have
ccurred more than once for each particular participant, the par-
icipant was censored at the time to the ﬁrst event (per time period (2015) 3415–3421 3417
analyzed). A priori analyses included comparisons of solicited and
unsolicited events, PDWIs, and SAEs by vaccine group overall, as
well as by severity grading and relationship among age groups and
over different time periods post-vaccination (0–7 days, 8–42 days,
43 days through study end, or over the entire study period). Post
hoc analyses included comparison of PDWI over the entire study
period, by study clinic documentation of past bronchodilator treat-
ment, as well as tachypnea identiﬁed at home and in the study clinic
by vaccine groups, overall and by age grouping. Analyses were per-
formed with SAS software (version.9.3; SAS Institute Inc., Cary, NC,
USA).
3. Results
3.1. Participant ﬂow
A total of 309 children were enrolled in the study (Fig. 1). After
enrollment, 9 children were found to meet study exclusion criteria,
did not receive study vaccine, and were discontinued from further
trial activities. Of the remaining children, 300 participants were
randomized and administered LAIV (150) or placebo (150). Of the
children who  received study vaccine, 297 (99.0%) participants had
weekly follow-up visits through study completion, and three (1.0%)
participants migrated out of the study area but provided safety data
until their departure.
3.2. Baseline characteristics
Children receiving LAIV and placebo were 24 through 35 months
(25.3% vs. 20.7%), 36 through 47 months (38.7% vs. 38.0%), and 48
through 59 months of age (36.0% vs. 41.3%) at the time of vaccina-
tion (Table 1). 131 children had a parent report that they previously
received medical treatment or been hospitalized for wheezing ill-
ness, with an equal percentage occurring in both study groups
(43.3% vs. 44.0%).A minority of children had previously been hospi-
talized for wheezing illness (6.7% vs. 8.0%). One child with a history
of hospitalization did not have a prior history of treatment for
wheezing illness.
3.3. Solicited adverse events
There were no immediate post-vaccination reactions in either
vaccine group. There were no statistically signiﬁcant differences of
participants with any solicited post-vaccination reactions between
vaccine groups within the ﬁrst 7 days post-vaccination (Table 2).
Among the solicited reactions in this time period, LAIV recipients
experienced 50 mild and 5 moderate events, while placebo recip-
ients experienced 52 mild and 2 moderate events. There were no
severe or life threatening solicited reactions. There were no imbal-
ances in solicited reactions between the vaccine and placebo groups
when analyzed by day during the ﬁrst 7 days post-vaccination over-
all, by severity grading, or by age group (data not shown).
Though not a protocol-deﬁned safety endpoint, solicited reac-
tions were systematically collected through the end of the study.
Through the 42 days post vaccination, as well as throughout
the entire study period, there were no statistically signiﬁcant
differences in participants with solicited reactions. There was a
non-signiﬁcant imbalance in tachypnea occurring during the day
8–42 day period following vaccination (n = 5 LAIV vs. n = 0 placebo,
p = 0.06). Tachypnea events were graded as present/absent only
without further severity classiﬁcation.
Given the imbalance in tachypnea between vaccine groups iden-
tiﬁed by FRAs in participant homes, we conducted a post hoc
analysis of tachypnea assessed in the study clinic among partici-
pants referred by FRAs or self-referring (Supplemental Tables 1 and
2). We  found no statistically signiﬁcant differences in participants
3418 J.R. Ortiz et al. / Vaccine 33 (2015) 3415–3421
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Fig. 1. Pa
ith tachypnea events as identiﬁed in the study clinic between
he study groups during the ﬁrst 7 days post-vaccination (2 LAIV
s. 5 placebo, p = 0.448). LAIV recipients, however, had signiﬁcantly
ore tachypnea events identiﬁed in the study clinic compared to
lacebo recipients (14 LAIV vs. 3 placebo, p = 0.010) from days 8–42
ost-vaccination. Most of these events occurred among children
4 through 35 months (8 LAIV and 1 in placebo, p = 0.035) and
8 through 59 months (4 LAIV and 0 in placebo, p = 0.044) of age.
here were no statistically signiﬁcant differences in participants
ith tachypnea between LAIV and placebo groups from days 43
able 1
articipant baseline data.
Characteristic (n, %) 
Number of participantsa
Age  group
24 through 35 months 
36  through 47 months 
48  through 59 months 
Female 
History of any asthma/wheezing therapy or hospitalization 
History of any asthma/wheezing therapy 
History of hospitalization with therapy for asthma/wheezing 
Stuntingb
No 
Mild  
Moderate/severe 
Concomitant medicationsc
Antibacterial 
Antipyretic 
Other  
a Seasonal inﬂuenza vaccine is not licensed, recommended or available to children in B
b Mild stunting deﬁned as height-for-age ≤−1 and ≥−2 SD and Moderate/Severe stun
edian value (http://whqlibdoc.who.int/hq/1997/WHO NUT 97.4.pdf).
c At the time of enrolment, three participants (2 placebo, 1 LAIV) were taking antihista
omeopathic remedies, two participants (1 placebo, 1 LAIV) were taking antitussives, on
LAIV)  was  taking an antimicrobial for giardiasis.0) An alyzed (n=150 )
ant ﬂow.
through study end or over the entire study period among all ages
or by age group. The number of children found to have tachypnea
events in the study clinic that had PDWI during the ﬁrst 7 days post-
vaccination was 1 LAIV vs. 1 placebo, and the number with PDWI
during days 8–42 days post-vaccination were 2 LAIV vs. 1 placebo.3.4. Unsolicited adverse events
Among all unsolicited adverse events identiﬁed by FRAs in
participant homes, there were statistically more participants
LAIV (n, %) Placebo (n, %)
150 (100.0%) 150 (100.0%)
38 (25.3%) 31 (20.7%)
58 (38.7%) 57 (38.0%)
54 (36.0%) 62 (41.3%)
73 (48.7%) 66 (44.0%)
65 (43.3%) 66 (44.0%)
65 (43.3%) 65 (43.3%)
10 (6.7%) 12 (8.0%)
29 (19.3%) 39 (26.0%)
62 (41.3%) 59 (39.3%)
59 (39.4%) 52 (34.6%)
1 (0.7%) 0 (0.0%)
1 (0.7%) 4 (2.7%)
5 (3.3%) 4 (2.7%)
angladesh, and none of the enrolled children had prior inﬂuenza vaccine exposure.
ting deﬁned as height-for-age <−2 or greater SD from the international reference
mines for cough or runny noses, two participants (1 placebo, 1 LAIV) were taking
e participant (LAIV) was  taking paracetamol for knee trauma, and one participant
J.R. Ortiz et al. / Vaccine 33 (2015) 3415–3421 3419
Table  2
Solicited adverse event by vaccine group in ﬁrst 7 days post-vaccination.
Solicited adverse event LAIV group (n = 150) n (%) Placebo group (n = 150) n (%) p-Value
Fever (measured ≥38.0) 5 (3.3%) 5 (3.3%) 1.000
Ear  pain 2 (1.3%) 2 (1.3%) 1.000
Cough 10 (6.7%) 8 (5.3%) 0.809
Runny  nose/nasal congestion 31 (20.7%) 34 (22.7%) 0.779
Sore  throat 2 (1.3%) 0 (0.0%) 0.498
Headache 1 (0.7%) 0 (0.0%) 1.000
Irritability/decreased activity 0 (0.0%) 0 (0.0%) –
Vomiting 2 (1.3%) 3 (2.0%) 1.000
Lethargy 0 (0.0%) 0 (0.0%) –
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aotes: (1) Events in this table were ascertained by daily Field Research Assistant (F
lacebo)  and cough (3 LAIV vs. 1 placebo). There were no severe events.
ith events among those who had received LAIV than placebo
uring the ﬁrst 7 days post-vaccination (n = 20 vs. n = 8, p = 0.028),
owever there was no difference between groups from days 8–42
ost-vaccination (37 vs. 27, p = 0.204), or from days 43 through
tudy end (79 vs. 91, p = 0.200). Similar proportions of participants
xperienced moderate events between LAIV and placebo groups
rom days 0–7 post-vaccination (3.3% vs. 0.0%), days 8–42 post-
accination (2.7% vs. 1.3%), and days 43 through study end (6.7%
s. 6.0%). Throughout the trial, there were similar numbers of LAIV
96) and placebo (94) participants who experienced unsolicited
eactions. Speciﬁc unsolicited adverse events occurring through-
ut the trial are detailed in Table 3. Of these, LAIV and placebo
articipants experienced moderate events (11.3% vs. 6.7%) and
ild events (52.7% and 56.0%).
.5. Protocol-deﬁned wheezing illness (PDWI)
PDWI events occurred throughout the trial (Fig. 2 and Supple-
ental Table 3). There were no statistically signiﬁcant differences
n participants experiencing PDWI between LAIV and placebo
roups throughout the entire study (n = 13 vs. n = 16, p = 0.697). All
DWI events were of mild severity. There were 38 total clinic visits
here PDWI was identiﬁed during the trial, with 6 participants
aving more than one clinic visit when PDWI was identiﬁed (Sup-
lemental Table 3). Fifteen PDWI cases had positive laboratory tests
or respiratory viruses (5 adenovirus, 7 respiratory syncytial virus,
 human metapneumovirus), although none of the PDWI cases had
nﬂuenza virus detected. In a post hoc analysis, we compared par-
icipants with PDWI events by age category and time period and
here were no signiﬁcant differences in events by vaccine group
data not shown). In a post hoc analysis, we compared participants
ith PDWI by study group among the subset of participants that
ad a history of treatment or hospitalization for asthma or wheez-
ng illness at baseline, and there was no statistical differences in
able 3
articipants with unsolicited adverse events (any vs. none), by vaccine group over the en
Adverse event classiﬁcation LAIV group (n = 150) n (%) 
Diarrheal illness 38 (25.3) 
Oral  thrush 26 (17.3) 
Boil/abscess/skin infection/ulcer/cyst 11 (7.3) 
Helminthiasis 9 (6.0) 
Scabies  8 (5.3) 
Abdominal pain/distension 5 (3.3) 
Allergy  6 (4.0) 
Fungal  infection 6 (4.0) 
Other  55 (36.7)
otes: (1) All Day 0–7 events were mild with the exception of 2 moderate diarrhea events
roup  events in the 0–7 day period were mild in severity. All Day 8 through study end ev
ral  thrush (1 LAIV vs. 1 placebo), Boil/Abscess/Skin Infection/Ulcer/Cyst (2 LAIV vs. 0 plac
nd  other classiﬁcations (9 LAIV vs. 6 placebo). (2) There were no severe adverse events.ome visits. (2) All events were mild except for moderate events fever (2 LAIV vs. 1
events occurring throughout the trial between LAIV and placebo
groups (5 vs. 13, p = 0.074)
3.6. Serious adverse events
There were six SAEs (Supplemental Table 4). All six occurred
among participants in the LAIV group. Three of the events resulted
in hospitalization. All events were moderate in severity, all
resolved, and none was  judged to be related to study vaccine
receipt. These SAEs included three due to traumatic injury and bone
fracture, and one each due to accidental overdose of paracetamol,
abdominal pain, and acute gastroenteritis. None of the participants
with SAEs had wheezing illness or other signs of acute respiratory
illness at the time of their events. All of the children with SAEs
recovered.
4. Discussion
Russian-backbone LAIV has the potential to be effective, afford-
able, and logistically feasible for immunization of children in
low-resource countries [17]. This randomized, placebo-controlled
trial was  the ﬁrst to prospectively assess wheezing illness after
receipt of a Russian-backbone LAIV. In this population of urban
Bangladeshi children with a high prevalence of wheezing illness
at baseline [18], LAIV was  well tolerated, and we found no sta-
tistically signiﬁcant differences in our primary safety endpoints:
solicited adverse events during the ﬁrst 7 days-post-vaccination
or other adverse events occurring throughout the study, including
unsolicited adverse events, PDWI, all cause hospitalizations, and
SAEs related to study vaccination.There were some event imbalances between treatment groups,
including six SAEs in the LAIV group as compared to none in the
placebo group. None of these SAEs had respiratory symptoms or
were judged to be related to the vaccine. Post hoc analyses of
tire study period.
Placebo group (n = 150) n (%) 2-sided Fisher’s exact
32 (21.3) 0.495
18 (12.0) 0.253
18 (12.0) 0.241
11 (7.3) 0.818
6 (4.0) 0.785
6 (4.0) 1.000
6 (4.0) 1.000
5 (3.3) 1.000
51 (34.0) 0.717
 and 3 moderate “other” events (all traumatic injury) in the LAIV group. All placebo
ents were mild except for moderate events diarrheal illness (3 LAIV vs.2 placebo),
ebo) abdominal pain/distension (1 LAIV vs.1 placebo), allergy (0 LAIV vs. 2 placebo)
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pig. 2. Protocol-deﬁned wheezing illness (PDWI) identiﬁed during illness visits by
nce  throughout the trial, total events summarized in the online supplement inclu
o  be counted per participant in each time period.
rial data found imbalances of tachypnea, deﬁned as a respiratory
ate ≥40 breaths/min, among two and four year old children but
ot among three year olds. While tachypnea can correlate with
heezing illness, a major safety endpoint for this trial, we found
o imbalance in PDWI. While Russian-backbone LAIV had never
een associated with wheezing illness, previous clinical trials of
he vaccine did not prospectively solicit this event and included
ew children younger than 24 months of age (the age group at risk
or wheezing in FluMist® trials) [6,19]. Larger studies with robust
afety evaluations will be necessary to better determine whether
achypnea or wheezing illness is also a safety concern in young
hildren receiving the Russian-backbone LAIV.
This trial should be interpreted in the context of its limitations.
he background rates of previous wheezing illness in these children
re higher than previous estimates from other developing countries
nd may  affect the generalizability of the safety results from this
ingle center study [20]. Children with wheezing illness who did
ot seek care at the study clinic or who did not meet the referral
riteria threshold upon seeking care in the clinic would not have
een captured by our safety surveillance. However, referral crite-
ia were sensitive, and would likely have missed few medically
mportant adverse events. While we found no imbalances in PDWI
r related SAEs between vaccine groups, the study was not pow-
red to detect signiﬁcant differences in rare events. Finally, while
e did ﬁnd imbalances in tachypnea among children two  and four
ears of age, these were not a priori analyses, participant denom-
nators were small, and we did not adjust analyses for multiple
omparisons. This ﬁnding should be interpreted with caution.
PATH is currently sponsoring two safety and efﬁcacy trials using
he SIIL LAIV among children in Bangladesh and Senegal [21,22].
hese larger trials with 1761 participants each will better assess
he risk of less common safety outcomes associated with vaccine
eceipt among pediatric age groups. Likewise, these efﬁcacy tri-
ls will allow risk-beneﬁt assessments to inform vaccine policy in
angladesh, Senegal, and other countries with high attack rates of
ediatric inﬂuenza [13,23].ne group. Note: Because some individuals had an adverse event coded more than
re events than are included in the safety analyses, which only allow a single event
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